PERSEPHONE
Who is this for?
Those with symptomatic COPD (have had ≥2 moderate OR ≥ 1 severe exacerbations in the past year)
Study:
This clinical trial evaluates the safety and efficacy of the investigational medication lunsekimig in adults with eosinophilic chronic COPD whose disease remains inadequately controlled despite standard treatment.